Lv55
1050 积分 2024-05-17 加入
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
23天前
已完结
Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression
1个月前
已完结
Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
1个月前
已完结
Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials
1个月前
已完结
Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation
2个月前
已完结
Independence of clinical events committees: A consensus statement from clinical research organizations
4个月前
已完结
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions — proceedings from the CEC Summit 2018
4个月前
已完结
Fourth universal definition of myocardial infarction (2018)
4个月前
已完结
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial
4个月前
已完结
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium
4个月前
已完结
皖公网安备34019202002308
